HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on InMed Pharmaceuticals (NASDAQ:INM) with a Buy rating and announces Price Target of $6.
Q2 2022 Outlook and 2022 Capital Expenditure Guidance
Our guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below